Health IT business news, financial edition - october 29, 2026. DirectTrust and GLEIF Partner on Verifiable Organizational Identity for Healthcare DirectTrust and the Global Legal Entity Identifier Foundation announced a partnership to develop a Qualification Agent model supporting adoption of verifiable Legal Entity Identifiers in U.S. healthcare. The initiative would enable qualified organizations to help establish and verify digital organizational identities, supporting trusted electronic transactions and healthcare information exchange. Vera Health Raises $32 Million for clinical AI search platform Vera Health announced a $28.5 million Series A led by Threshold Ventures, with participation from Mantis VC and SV Angel. Existing investors Y Combinator and Gradient tripled down, bringing the company's total funding to $32 million. The company will use the funds to expand its clinical AI platform and build partnerships with medical societies, publishers and health systems. Southwest General Expands its Partnership with Oracle Oracle announced that Southwest General Health Center in Ohio is expanding its technology relationship to include Oracle Health Patient Accounting, Oracle Health Data Intelligence and Oracle Fusion Cloud Applications. The expansion builds on Southwest General's existing Oracle Health electronic health record and AI documentation capabilities and will integrate clinical, revenue cycle, financial and operational information across the organization. The Springs Living and PointClickCare Announce Technology Co-Development Partnership The Springs Living and PointClickCare announced a strategic partnership to develop technology connecting senior living communities with healthcare services. The agreement will involve PointClickCare working with frontline teams at several Springs Living communities in Oregon to design, test and implement technology supporting resident care and staff workflows. Hackensack Meridian Health Commits $30M to Epic Implementation as Part of Hunterdon Health Merger Hackensack Meridian Health and Hunterdon Health announced a definitive agreement for Hunterdon Health to join the Hackensack Meridian network. As part of the proposed merger, Hackensack Meridian will invest $200 million in facilities, programs and expanded access to care, along with $30 million to implement the Epic electronic health record across Hunterdon Medical Center, ambulatory locations, affiliated practices and participating independent physicians. The transaction remains subject to regulatory approval. Mergers and acquisitions. Austco Healthcare to Acquire RTM Solutions and CareTech Systems Austco Healthcare announced agreements to acquire RTM Solutions, a provider of real-time monitoring and systems-integration software for healthcare facilities, and CareTech Systems, a developer of nurse call technology. Contract announcements. Pathos AI Signs $55M Data Agreement With Tempus AI, Expands Collaboration With Bristol Myers Squibb Pathos AI announced strategic collaborations with Bristol Myers Squibb and Tempus AI to advance AI-driven drug development for Alzheimer's disease and other neurological conditions. Under a five-year, $55 million agreement, Tempus will develop a de-identified longitudinal dataset covering hundreds of thousands of patients with neurological conditions for use by Pathos. Bristol Myers Squibb will gain access to Pathos' Foundry AI platform, including exclusive rights for neuroscience development programs over three years. St. Luke's Health System Selects hellocare.ai for Enterprise Virtual Care Deployment hellocare.ai announced that St. Luke's Health System selected its AI-assisted virtual care platform for deployment across hospitals and inpatient facilities in southern Idaho. The agreement includes virtual nursing, virtual patient observation, telehealth and AI-supported care coordination capabilities. PacBio and Verily Health Announce Multiyear Collaboration for Biomedical AI PacBio and Verily Health announced a multiyear strategic collaboration to integrate PacBio's HiFi sequencing technology with Verily's healthcare data and AI platform. The agreement will connect genomic sequencing workflows with clinical data to create datasets for biomedical research, AI model development and precision medicine applications. Healthcare Triangle Subsidiary Secures Multiyear Health IT Contracts Healthcare Triangle announced that its Purpose Health subsidiary signed several multiyear agreements, including a master services agreement with a university health system for electronic health record optimization and cybersecurity services. The company also secured an agreement to provide IT services supporting a healthcare business unit's global technology center and reported additional advisory work involving MEDITECH and rural health transformation initiatives. Oracle and AstraZeneca Announce AI Collaboration for Clinical Research Oracle and AstraZeneca announced a nonbinding agreement to explore applications of AI, cloud technology and real-world data in clinical research. The companies plan to evaluate tools for identifying clinical trial participants, improving evidence generation and connecting research insights with clinical workflows. Initial work will focus on hypertension care and clinical research in Abu Dhabi, with additional projects under consideration. Venture capitol and funding. Kivo Health Raises $10M in Series A At-home virtual care provider Kivo Health raised $10 million in Series A funding, to scale AI-powered care for seniors with chronic disease. Sunlight AI Raises $17.4M in Seed Funding to Support Independent Medical Practices Sunlight AI announced its launch and $17.4 million in seed funding to develop an AI-enabled operating platform for independent medical practices. The round was led by Lan Xuezhao, founder of Basis Set Ventures, with participation from Sofeon Ventures, Social Leverage, Actions Capital, Overlook Ventures and Early Light Ventures. The company also announced its acquisition of Bradford Medical Associates as part of its strategy to provide administrative, financial and operational support to independent physicians. XRlabs Raises $8.4M in Seed Funding for AI-Powered Surgical Platform XRlabs announced $8.4 million in seed funding led by Playground Global, with participation from Eka Ventures. The financing will support development and clinical deployment of the company's AI powered surgical platform, which combines live surgical video, navigation data and patient imaging to provide real-time information during procedures. XRlabs also announced that former Medtronic Chairman and CEO Omar Ishrak has joined its board as chair. Pathos AI Raises $237M Series E at $3B Valuation Pathos AI announced a $237 million Series E financing round led by Bristol Myers Squibb, with participation from existing investors. The round values the AI-driven drug development company at approximately $3 billion. The funding will support expansion of its Foundry AI platform and clinical development of its oncology pipeline. Baba Raises $40M Series A to Expand AI-Enabled Medicare Care Coordination Baba, an AI-enabled care coordination company serving Medicare and Medicaid populations, announced a $40 million Series A led by FirstMark Capital, with participation from CVS Health Ventures, Valtruis, General Catalyst, Genius Ventures and Ground Up Ventures. The funding will support expansion of the company's clinical care teams, AI research and partnerships with health plans, as well as its value-based care arrangements. Making the cut, milestones, accolades, awards and more. Hackensack Meridian Health Commits $30M to Epic Implementation as Part of Hunterdon Health Merger Hackensack Meridian Health and Hunterdon Health announced a definitive agreement for Hunterdon Health to join the Hackensack Meridian network. As part of the proposed merger, Hackensack Meridian will invest $200 million in facilities, programs and expanded access to care, along with $30 million to implement the Epic electronic health record across Hunterdon Medical Center, ambulatory locations, affiliated practices and participating independent physicians. The transaction remains subject to regulatory approval.

Key points. * Bristol Myers leads Pathos AI's new funding round * Tempus AI to build Pathos a neurology dataset * What Bristol Myers gets from Pathos's Foundry platform Pathos AI announced partnerships with Bristol Myers Squibb (BMY) and Tempus AI (TEM) on Friday to develop AI tools and a patient dataset for research into Alzheimer's and other neurological diseases. Bristol Myers also led Pathos's Series E funding round, which raised $237 million and valued the New York-based company at about $3 billion. "Neurological diseases demand more than any one company can bring on its own," Pathos chief executive Iker Huerga said in the company's release. Bristol Myers also gets access to Pathos's AI platform for its drug research. Tempus shares rose about 6% on Friday, while Bristol Myers shares fell about 2.4%. Pathos is privately held. Tempus will build the dataset. Under a five-year, $55 million agreement, Pathos will license a de-identified dataset that Tempus plans to build from "hundreds of thousands of patients with neurological conditions." De-identified means names and other details that could identify a patient are removed. The release says the data is designed to track outcomes over time. Tempus will apply the infrastructure and expertise it has built in oncology to create the dataset, according to the release. The companies gave no date for when it will be ready. Pathos will run the data through Foundry, its AI platform, to "generate and test hypotheses on disease biology" and to inform the design of "more targeted, adaptive clinical trials." Pathos built that approach in cancer drug development, where the release says it guides decisions across the company's clinical-stage pipeline. "Making meaningful progress against a disease as devastating as Alzheimer's requires unprecedented data scale and computing power," said Eric Lefkofsky, Tempus's founder and chief executive. Bristol Myers gets access to Foundry. Bristol Myers gets non-exclusive access to Foundry across its broader research and development portfolio. It also gets what the release calls "three-year exclusive rights to support its neuroscience development programs." The release doesn't say whether those rights bar other companies from using Foundry for neuroscience work. The drugmaker aims to "identify patients most likely to benefit from potential therapies and design more precise clinical trials," according to the release. "Our investment in Pathos reflects our commitment to applying advanced AI and data science across research and development to accelerate innovation for patients," said Simon Davies, senior vice president and head of data and quantitative sciences at Bristol Myers. The release doesn't say how much of the Series E Bristol Myers put in or what it pays for the platform access. It also names no specific Bristol Myers drug program the platform will support. Pathos plans to spend on Foundry and cancer drugs. Pathos plans to use the new money to scale Foundry and advance its pipeline, including the experimental cancer drug JSKN016 and a breast cancer drug partnered with AstraZeneca, Reuters reported. The company's clinical-stage programs cover prostate cancer, multiple myeloma, lung cancer, breast cancer, and other solid tumors. "Intelligence alone does not bring a therapy to market," Huerga said. The AIStockWire daily brief Top movers, notable insider buys and fresh Congress trades in your inbox each morning. Free. No spam, ever. Unsubscribe in one click.